ag
antigen
apc
antigen
present
cell
apm
antigenprocess
machineri
bh
bleomycin
hydrolas
bp
base
pair
ciita
class
ii
transactiv
protein
clip
class
ii
invari
chain
peptid
ctl
cytotox
lymphocyt
dc
dendrit
cell
er
endoplasm
reticulum
ga
gammainterferonactiv
site
ifn
interferon
il
interleukin
irf
interferon
regulatori
factor
isg
interferonstimul
gene
ifnstimul
gene
factor
isr
interferonstimul
respons
element
jak
janu
kinas
lp
lipopolysaccharid
mapk
mitogenactiv
protein
kinas
mca
methylcholanthren
mhc
major
histocompat
complex
nf
nuclear
factor
nk
natur
killer
pkc
protein
kinas
c
rcc
renal
cell
carcinoma
sclc
smallcel
lung
carcinoma
soc
suppressor
cytokin
signal
stat
signal
transduc
activ
transcript
ta
tumor
antigen
tap
transport
associ
antigen
process
tcr
cell
receptor
tfb
transcript
factorbind
site
tnf
tumor
necrosi
factor
tpn
tapasin
tppii
tripeptidyl
peptidas
ii
tsa
trichostatin
tyk
tyrosin
kinas
uirr
upstream
interferon
respons
region
upstream
stimulatori
factor
wt
wild
type
interferon
ifn
repres
protein
secret
cell
respons
variou
stimuli
provid
basi
understand
evolut
structur
function
well
pathway
cytokin
receptor
pestka
pestka
et
al
exert
pleiotrop
effect
involv
host
respons
bacteri
viral
infect
tumor
surveil
mechan
well
innat
adapt
immun
respons
decker
et
al
pestka
et
al
stetson
medzhitov
takaoka
yanai
addit
ifn
first
cytokin
use
treatment
tumor
patient
howev
suggest
tumor
cell
might
develop
either
transient
perman
ifn
insensit
phenotyp
link
cytotox
resist
might
lead
escap
tumor
cell
immun
surveil
summar
current
knowledg
pleiotrop
function
ifn
mediat
variou
biolog
respons
ii
mechan
action
transduct
pathway
iii
effect
type
type
ii
ifn
express
level
molecul
involv
proper
major
histocompat
complex
mhc
class
class
ii
antigen
process
present
tumor
cell
iv
frequenc
underli
molecular
mechan
ifn
resist
tumor
associ
alter
mhc
class
ii
antigenprocess
machineri
v
clinic
relev
aberr
ifn
signal
elucid
mechan
lead
dysregul
ifn
signal
transduct
cascad
trigger
immun
dysfunct
tumor
immun
escap
benefit
design
strategi
revers
defici
could
clinic
relev
interferon
ifn
famili
multifunct
cytokin
origin
describ
antivir
cytokin
therebi
protect
cell
viral
infect
isaac
lindenmann
howev
base
current
knowledg
exhibit
broad
spectrum
activ
includ
antiprolif
immunomodulatori
antiinflammatori
apoptosisinduc
stressmedi
effect
well
regul
cell
differenti
step
angiogenesi
amadori
baccala
et
al
theofilopoulo
et
al
ifn
famili
divid
type
type
ii
type
iii
ifn
type
ifn
consist
ifnmemb
singl
member
ifn
ifn
ifn
ifn
respect
cluster
chromosom
contrast
type
ii
ifn
repres
singl
gene
ifn
encod
chromosom
decker
et
al
recent
type
iii
ifn
discov
novel
class
antivir
cytokin
classifi
oesterlund
et
al
sheppard
et
al
uze
monneron
ifn
bind
two
distinct
cell
surfac
receptor
type
ii
ifn
signal
common
chain
therebi
activ
discret
relat
pathway
lead
transcript
activ
socal
interferonstimul
gene
isg
tabl
fig
isg
repres
function
divers
group
gene
involv
mani
cellular
activ
transcript
translat
regul
cell
cycl
apoptosi
intracellular
commun
well
process
present
antigen
transcript
activ
isg
necessari
mediat
effect
ifn
divers
activ
ifn
use
treatment
variou
diseas
chronic
viral
infect
like
hepat
c
multipl
sclerosi
hematopoiet
malign
well
solid
tumor
includ
renal
cell
carcinoma
rcc
melanoma
ifn
therapi
shown
reduc
rate
relaps
mortal
tumor
patient
kirkwood
et
al
howev
last
decad
progress
concern
adjuv
therapi
tumor
patient
achiev
therefor
better
knowledg
underli
molecular
mechan
ifn
action
may
lead
improv
effect
applic
design
innov
intellig
treatment
strategi
use
ifn
alon
combin
therapeut
wealth
inform
avail
molecular
process
underli
ifninduc
signal
cascad
bind
ifn
specif
receptor
lack
intrins
kinas
activ
induc
oligomer
receptor
subunit
trigger
divers
signal
pathway
fig
therebi
lead
transcript
regul
plethora
target
gene
kaur
et
al
li
et
al
schindler
et
al
physiolog
relev
ifndepend
signal
transduct
cascad
includ
statjak
pathway
establish
gener
character
mice
target
disrupt
gene
encod
respect
platania
ramana
et
al
type
type
ii
ifn
receptor
ifnr
initi
activ
jakstat
cascad
consist
four
janu
kinas
seven
signal
transduc
activ
transcript
fig
ifn
signal
transduct
cascad
defect
pathway
type
type
ii
receptor
transmembran
glycoprotein
whose
extracellular
domain
serv
ifnbind
site
wherea
cytoplasm
domain
associ
member
jak
kinas
famili
initi
signal
transmiss
dunn
et
al
upon
bind
specif
receptor
type
type
ii
ifn
induc
number
signal
transduct
cascad
involv
phosphoryl
variou
compon
jak
stat
recruit
receptor
stat
becom
phosphoryl
form
homoor
heterodim
migrat
nucleu
bind
specif
sequenc
promot
target
gene
type
ifninduc
signal
induc
homodimer
heterodimer
associ
cytosol
transcript
factor
ifnregulatori
factor
form
trimer
complex
known
ifnstimul
gene
factor
activ
transcript
bind
isr
type
ii
ifn
associ
kinas
jak
phosphoryl
form
homodim
transloc
nucleu
activ
transcript
bind
ga
sequenc
ifnmedi
signal
control
sever
mechan
includ
dephosphoryl
mediat
protein
tyrosin
phosphatas
inhibit
jak
mediat
suppressor
cytokin
signal
proteasom
degrad
jak
inhibit
mediat
protein
inhibitor
activ
shinya
et
al
yu
jove
stat
transcript
factor
repres
cytosol
protein
amino
acid
compos
extracellular
domain
play
import
role
associ
stat
receptor
molecul
ii
ligandbind
domain
iii
intracellular
domain
respons
stat
dimer
format
induc
express
ifnrespons
gene
activ
ifnstimul
respons
element
isr
contain
promot
yu
jove
howev
becom
appar
activ
jakstat
pathway
alon
suffici
gener
biolog
activ
ifn
exist
accumul
evid
sever
ifnregul
signal
element
cascad
requir
gener
mani
ifn
respons
oper
independ
jakstat
pathway
wherea
other
cooper
stat
optim
transcript
regul
target
gene
includ
particular
pathway
link
cellular
stress
cell
death
like
mitogenactiv
protein
kinas
mapk
stressinduc
kinas
protein
kinas
c
pkc
signal
cascad
pkc
known
involv
ifnandsign
pathway
kwon
et
al
context
noteworthi
ifn
ifn
ifncascad
exhibit
overlap
activ
also
clearli
differ
featur
fig
levi
et
al
engag
type
ifn
receptor
ifnr
ifnbind
stimul
crosslink
ifnr
chain
therebi
bring
receptorassoci
kinas
close
proxim
trigger
activ
lead
phosphoryl
serv
dock
site
activ
kinas
subsequ
phoshoryl
respect
phosphoryl
stat
form
heterodim
associ
interferon
regulatori
factor
irf
undergo
tyrosin
phosphoryl
form
ifnstimul
gene
factor
turn
transloc
nucleu
bind
specif
element
known
isr
present
promot
certain
isg
initi
transcript
broad
varieti
gene
addit
phosphoryl
stat
complex
combin
differ
statcontain
complex
form
transloc
nucleu
bind
ifn
activ
site
ga
lead
transcript
gene
caraglia
et
al
noteworthi
ifncan
also
activ
role
ifn
mediat
activ
still
elucid
uddin
et
al
contrast
ifnmainli
activ
howev
one
specul
fine
balanc
differ
stat
complex
might
account
specif
respons
repres
key
mechan
ifn
induc
activ
ifnact
heterodim
consist
express
cell
therebi
upregul
specif
gene
bind
ifniniti
lead
format
homodim
consecut
attract
chain
homodim
constitut
associ
phosphoryl
tyrosin
intracellular
domain
serv
dock
site
latent
cytosol
transcript
factor
subsequ
phosphoryl
tyrosin
serin
lead
homodimer
molecul
form
complex
name
activ
factor
gaf
transloc
nucleu
upregul
transcript
ifn
regul
gene
includ
particular
interferonregul
factor
irf
repres
transcript
activ
wherea
constitut
express
gener
act
transcript
repressor
harada
et
al
subsequ
activ
transcript
caspas
gene
involv
apoptosi
next
gene
encod
major
histocompat
complex
mhc
particular
compon
mhc
class
class
ii
antigenprocess
machineri
apm
well
microglobulin
locat
chromosom
molecul
antigenprocess
pathway
requir
initi
trigger
proper
tcell
respons
respect
addit
cooper
ubiquit
express
transactiv
factor
upstream
stimulatori
factor
usf
activ
transcript
class
ii
transactiv
protein
promot
iv
ciitapiv
control
express
mhc
class
ii
molecul
chen
et
al
express
mhc
class
class
ii
molecul
critic
present
antigen
essenti
gener
adapt
immun
respons
cresswel
et
al
jensen
last
decad
cytotox
lymphocyt
ctl
implic
main
effector
cell
antitumor
respons
recogn
attack
tumor
cell
present
intracellular
antigen
deriv
differ
nonself
peptid
surfac
interact
tcell
receptor
tcr
mhc
class
peptid
complex
gener
present
antigen
ag
requir
coordin
express
sever
gene
fig
briefli
endogen
synthes
protein
cleav
multicatalyt
proteasom
complex
particular
ifn
regul
proteasom
subunit
low
molecular
weight
protein
lmp
peptid
trim
cytosol
enzym
exampl
tripeptidyl
peptidas
tpp
ii
bleomycin
hydrolas
bh
gener
correct
nterminu
kloetzel
rock
et
al
peptid
transport
cytosol
endoplasm
reticulum
er
via
transport
associ
antigen
process
tap
heterodim
consist
subunit
lumen
er
mhc
class
assembl
occur
assist
variou
chaperon
calnexin
calreticulin
oxido
thiol
reductas
tapasin
tpn
tpn
facilit
peptid
load
onto
mhc
class
molecul
success
peptid
load
mhc
molecul
releas
peptid
load
complex
trimer
consist
mhc
class
heavi
chain
hc
mpeptid
transport
transgolgi
apparatu
cell
surfac
present
ctl
thu
proper
express
major
compon
complex
mhc
class
apm
compon
obligatori
effect
tcell
recognit
tumor
groettrup
et
al
jensen
selig
et
al
recent
demonstr
cell
also
import
proper
antitumor
immun
respons
drozina
et
al
jensen
cell
recogn
via
tcr
antigen
present
mhc
class
ii
molecul
contrast
mhc
class
antigen
express
nucleat
adult
cell
express
heterodimer
mhc
class
ii
molecul
also
repres
transmembran
glycoprotein
highli
restrict
preferenti
found
cell
surfac
profession
antigen
present
cell
apc
howev
mhc
class
ii
antigen
express
induc
cell
type
variou
cytokin
particular
ifn
mhc
class
ii
express
mainli
control
class
ii
transactiv
protein
ciita
act
master
regul
coordin
constitut
ifn
induc
express
also
involv
pkc
delta
kwon
et
al
giroux
et
al
ciita
interact
transcript
factor
rfx
nfi
creb
van
den
cytosol
endogen
peptid
gener
proteasom
trim
peptidas
transport
er
via
heterodimer
tap
erap
involv
final
aminotermin
trim
peptid
load
mhc
class
molecul
peptid
assist
chaperon
tapasin
also
compon
plc
upon
peptid
load
plc
dissoci
transport
via
tran
golgi
cell
surfac
expos
cytotox
lymphocyt
b
mhc
class
ii
pathway
mhc
class
ii
molecul
assembl
er
invari
chain
li
contain
endosom
target
signal
complex
transport
endosom
compart
ii
cleav
number
proteas
leav
clip
fragment
occupi
peptidebind
groov
hladm
catalyz
releas
clip
exchang
antigen
peptid
hladm
edit
repertoir
mhc
class
iipeptid
complex
transport
cell
surfac
recognit
lymphocyt
exogen
protein
intern
endosom
pathway
differ
mechan
unfold
cleav
catalyz
differ
proteas
addit
yield
peptid
trim
bind
mhc
class
ii
molecul
elsen
et
al
therebi
form
enhanceosom
govern
mhc
class
ii
transcript
addit
coordin
express
variou
mhc
class
ii
apm
compon
exist
mainli
exogen
antigen
phagocytos
apc
direct
lysosom
cleav
small
peptid
fragment
fig
mhc
class
ii
antigen
assembl
er
peptidebind
groov
molecul
initi
occupi
invari
chain
degrad
class
ii
invari
chain
peptid
clip
fragment
seri
key
cleavag
event
therebi
protect
mhc
class
iibind
groov
load
mhc
class
ii
molecul
exogen
deriv
peptid
assist
chaperonelik
compon
hladm
result
exchang
clip
fragment
antigen
hladm
edit
peptid
present
cell
catalyz
multipl
round
peptid
exchang
possibl
favor
stabl
complex
peptideload
mhc
class
ii
molecul
transport
cell
surfac
present
lymphocyt
profession
apc
exogen
antigen
gain
access
mhc
class
pathway
distinct
crosspresent
mechan
furthermor
endosom
mhc
class
ii
load
pathway
could
also
receiv
peptid
deriv
endogen
antigen
autophagi
mechan
dengjel
et
al
schmid
et
al
promot
mhc
class
class
ii
apm
compon
intens
character
exert
similar
also
uniqu
properti
concern
promot
mhc
class
apm
compon
contain
tata
caat
box
wherea
other
complet
lack
regulatori
domain
promot
addit
noteworthi
transcrib
share
bidirect
promot
base
pair
bp
separ
atg
translat
initi
codon
wright
et
al
promot
major
mhc
class
apm
compon
contain
combin
distinct
transcript
factorbind
site
tfb
like
creb
nuclear
factor
nf
b
exhibit
ifnrespons
element
hint
toward
regul
irf
chatterjeekishor
et
al
fig
term
mhc
class
ii
pathway
promot
invari
chain
hladmdo
mhc
class
ii
hc
respect
contain
similar
also
distinct
transcript
factorbind
site
wherea
contain
ifnrespons
element
promot
except
repres
ciita
regul
multipl
promot
differ
tfb
composit
exist
three
tissuespecif
promot
ciita
pi
pii
piii
one
promot
control
constitut
ciita
express
dendrit
cell
dc
wherea
anoth
specif
constitut
express
b
cell
ciitapiv
regul
induct
ciita
express
differ
cell
type
contain
sever
ci
element
includ
put
nfb
site
overlap
site
ifnactiv
sequenc
ga
e
box
irf
element
dong
et
al
muhlethalermottet
et
al
thu
activ
differ
mhc
class
ii
apm
compon
promot
induc
differ
extent
type
type
ii
ifn
respect
ifni
stronger
induc
compar
type
ifn
wherea
combin
substanc
exert
addit
even
synergist
effect
mhc
class
ii
apm
compon
activ
adapt
immun
respons
ifn
particular
ifn
partial
due
transcript
activ
gene
encod
mhc
class
class
ii
antigen
respect
apm
compon
invari
chain
hladmdo
ciita
tap
tpn
lmp
fig
promot
structur
major
apm
compon
structur
repres
promot
major
apm
compon
schemat
illustr
demonstr
number
transcript
factorbind
site
nfb
creb
well
interferon
regulatori
respons
element
isr
involv
induc
cytokin
decreas
absenc
mhc
class
molecul
observ
divers
human
tumor
type
garrido
algarra
garrido
et
al
garrido
et
al
increas
proport
tumor
found
total
select
hla
allel
loss
support
theori
alter
hla
express
phenotyp
repres
major
mechan
tumor
escap
tcell
recognit
due
downmodul
present
immunodomin
tumor
antigen
distinct
hla
class
abnorm
includ
total
loss
downregul
hla
class
antigen
paschen
et
al
hla
haplotyp
loss
ramal
et
al
hla
locu
allel
loss
jimenez
et
al
describ
tumor
origin
differ
tissu
multipl
molecular
mechan
identifi
respons
chang
garrido
algarra
mechan
underli
total
partial
loss
hla
class
antigen
tabl
ii
includ
mutat
microglobulin
gene
perez
et
al
loss
heterozygos
loh
mhc
gene
maleno
et
al
caus
total
hla
class
downregul
compris
defect
regul
differ
compon
mhc
class
antigen
process
structur
defect
apm
compon
correct
cytokin
treatment
therefor
restor
hla
class
surfac
antigen
express
tcellbas
therapi
may
effect
due
irrevers
loss
hla
class
molecul
import
select
appropri
immunotherapi
given
cancer
patient
abnorm
express
variou
mhc
class
apm
compon
occur
high
frequenc
human
tumor
distinct
origin
like
smallcel
lung
carcinoma
sclc
melanoma
colon
carcinoma
breast
carcinoma
renal
cell
carcinoma
hematolog
malign
frequent
associ
malign
transform
tabl
ii
phenotyp
allow
tumor
cell
evad
recognit
mhc
class
irestrict
tumor
antigen
ta
specif
ctl
mutat
differ
apm
compon
appear
rare
event
postul
dysregul
rather
structur
alter
major
caus
aberr
apm
compon
express
fernandez
et
al
ramal
et
al
selig
et
al
tabl
ii
hypothesi
support
experi
identifi
mutat
molecul
ii
character
apm
promot
activ
tumor
iii
determin
posttranscript
regulatori
mechan
iv
treat
tumor
cell
ifn
analyz
whether
defici
apm
compon
express
could
overcom
cytokin
inde
impair
apm
compon
express
tumor
cell
could
often
restor
ifn
andor
ifntreat
ifnmedi
upregul
apm
compon
often
result
enhanc
mhc
class
surfac
express
requir
gener
effect
antitumorspecif
immun
respons
inde
ifninduc
upregul
apm
compon
improv
antitumorspecif
ctl
respons
selig
et
al
tajima
et
al
therefor
repres
valuabl
strategi
treatment
patient
apm
compon
defici
howev
case
tumor
remain
insensit
ifn
treatment
despit
lack
structur
alter
apm
compon
rather
suggest
impair
ifn
signal
transduct
unrespons
ifn
treatment
analyz
number
differ
tumor
type
accord
kaplan
et
al
frequent
found
human
cancer
approxim
melanoma
nonadenocarcinoma
lung
tumor
cell
line
analyz
exhibit
quantit
reduct
ifnsensit
lung
adenocarcinoma
cell
line
total
unrespons
ifn
data
extend
recent
studi
melanoma
cell
line
analyz
abil
upregul
mhc
class
surfac
antigen
respons
stimul
ifn
total
unrespons
ifnwa
found
melanoma
cell
line
rodriguez
et
al
howev
number
tumor
type
tumor
sampl
analyz
ifn
resist
still
limit
requir
studi
order
determin
frequenc
relev
molecular
mechan
defici
noteworthi
impair
ifnrespons
despit
function
ifninduct
may
exist
hand
lack
ifnrespons
also
found
presenc
ifnsensit
suggest
ifn
signal
transduct
cascad
coordin
regul
tumor
cell
import
involv
ifn
signal
transduct
pathway
transcript
regul
apm
promot
establish
exist
limit
inform
underli
molecular
mechan
defect
ifninduc
apm
compon
express
impair
could
occur
differ
step
along
ifn
signal
transduct
pathway
might
involv
sequenc
abnorm
andor
differ
regulatori
process
transcript
posttranscript
epigenet
control
fig
tabl
iii
physiolog
relev
statjak
pathway
establish
mice
target
disrupt
gene
lack
activ
associ
loss
ifnto
induc
growth
arrest
apoptosi
well
increas
tumorgen
sexl
et
al
howev
observ
ifnrespons
respect
growth
inhibit
might
also
attribut
ifninduc
hayashi
et
al
far
exist
limit
inform
regard
molecular
mechan
ifn
resist
tumor
huang
et
al
lesinski
et
al
wellbrock
et
al
wong
et
al
base
current
knowledg
involv
transcript
regul
dual
promot
loss
express
may
attribut
defici
regulatori
factor
regard
ifnresist
rcc
cell
line
associ
defect
induct
could
restor
addit
supernat
pmastimul
peripher
mononuclear
cell
brinckmann
et
al
effect
appear
mediat
ifnalthough
cytokin
might
also
involv
process
addit
loss
ifn
mediat
upregul
mhc
class
apm
compon
rcc
cell
line
appear
due
lack
activ
upon
ifnstimul
protein
express
phosphoryl
presenc
ifn
ifn
mediat
induc
restor
gene
transfer
andor
rcc
cell
wherea
overexpress
increas
express
independ
ifn
therefor
loss
induct
associ
defect
earli
step
ifnsign
transduct
pathway
dovhey
et
al
furthermor
associ
impair
phosphoryl
loss
ifnmedi
hla
class
induct
also
found
melanoma
cell
line
rodriguez
et
al
absenc
phosphoryl
least
partial
due
constitut
express
suppressor
cytokin
signal
soc
protein
could
mediat
kinas
inhibit
via
soc
phosphatas
modul
ifnmedi
signal
bind
autophosphoryl
site
target
bound
proteasom
degrad
waiboci
et
al
addit
express
correl
melanoma
progress
confer
growth
advantag
komyod
et
al
li
et
al
anoth
studi
ifnresist
associ
express
resist
cell
line
differ
sensit
cell
constitut
express
absenc
low
degre
activ
follow
ifntreat
short
durat
cytokin
activatori
signal
fojtova
et
al
express
ifn
respons
gene
also
reduc
choriocarcinoma
cell
jar
comparison
epitheli
cell
line
hela
choi
et
al
mediat
compromis
tyrosin
phosphoryl
tyrosin
reduc
express
addit
inhibit
tyrosin
phosphatas
result
increas
phosphoryl
ifn
induc
gene
express
cell
choi
et
al
impair
express
defici
phosphoryl
also
observ
primari
trophoblast
cell
line
suggest
defect
clinic
relev
besid
posttransl
regul
compon
ifn
signal
cascad
absenc
ifn
mediat
mhc
class
express
control
epigenet
alter
pathway
inde
methyl
affect
bind
lead
abrog
transactiv
rodriguez
et
al
treatment
demethyl
agent
dac
restor
express
consecut
led
reconstitut
ifn
mediat
mhc
class
induc
studi
identifi
ifn
unrespons
attribut
low
express
rather
absenc
phosphoryl
abril
et
al
xi
et
al
absenc
express
correl
methyl
promot
xi
et
al
final
exist
evid
genet
instabl
tumor
cell
may
lead
modul
express
ifnr
case
report
associ
cancer
prognosi
instanc
loss
ifnr
independ
predict
poor
prognosi
ovarian
cancer
may
respons
limit
success
outcom
treatment
ovarian
cancer
ifn
duncan
et
al
multipl
activ
ifn
tumor
cell
might
coordin
antitumor
immun
respons
earli
recognit
andor
elimin
cancer
cell
innat
immun
system
transit
immun
attack
adapt
immun
system
dunn
et
al
ifnon
tumor
cell
immunogen
mediat
immun
respons
direct
tumor
cell
distinct
mechan
ifncan
downregul
express
ligand
time
increas
express
mhc
class
molecul
bui
et
al
vitro
treatment
ifndecreas
death
nk
cell
independ
express
hla
class
molecul
wherea
increas
mhc
class
express
increas
sensibl
ctlmediat
lysi
besid
vitro
result
also
exist
inform
abnorm
ifn
signal
occur
vivo
exhibit
impair
proteasom
function
femal
develop
uterin
leiomyosarcoma
month
age
thu
develop
spontan
human
uterin
leiomyosarcoma
might
probabl
due
defect
earli
step
ifn
signal
cascad
inde
defect
express
tumor
associ
mutat
atpbind
region
kinas
domain
therebi
affect
kinas
activ
neither
express
product
degrad
hayashi
et
al
allow
tumor
cell
evad
antitumorspecif
immun
differ
tumor
type
immunosuppress
associ
activ
inhibit
dc
function
report
yu
jove
biolog
function
differ
term
cell
growth
induct
antitumor
immun
respons
wherea
abrog
growth
mediat
antitumor
effect
promot
cell
prolifer
tumorigen
shown
melanoma
head
neck
squamou
carcinoma
tumor
entiti
express
associ
tumor
progress
mediat
immun
suppress
addit
unphosphoryl
phosphoryl
coordin
upregul
ifnand
ifnand
may
repres
marker
dynam
mechan
melanoma
progress
host
respons
use
methylcholanthren
mca
untreat
ifnr
signific
tumor
develop
observ
ifnr
control
mice
cross
mice
mice
result
spontan
rapid
tumor
develop
particular
teratoma
hemangioma
chondrocytoma
wherea
lymphoid
tumor
gener
develop
ifn
sensit
mice
interestingli
ifnsensit
tumor
cell
transfect
domin
neg
ifnr
mutant
grew
faster
untransfect
tumor
reject
upon
treatment
lipopolysaccharid
lp
effect
elimin
control
tumor
furthermor
downregul
ifnr
associ
loss
fa
function
link
tumor
progress
yang
et
al
thu
ifnrespons
import
mechan
control
tumor
growth
increas
respons
metastasespromot
agent
might
induc
mani
mediat
microenviron
melanoma
includ
type
type
ii
ifn
cytokin
cooper
tnf
involv
posit
interplay
pkc
signal
transduct
bianchini
et
al
data
suggest
multipl
signal
gener
host
inflammatori
cell
accompani
cooper
invas
properti
tumor
cell
therefor
strategi
target
crosstalk
among
tumor
host
cell
microenviron
need
prevent
tumor
growth
chimer
retptc
rearrang
transformationpapillari
thyroid
carcinoma
oncoprotein
constitut
express
papillari
thyroid
cancer
abl
phosphoryl
accompani
express
hwang
et
al
associ
enhanc
transcript
ciita
consequ
mhc
class
ii
express
papillari
thyroid
carcinoma
cell
explain
immun
cell
infiltr
retptcposit
cancer
furthermor
synergist
activ
tnfand
ifnon
ciita
found
thyroid
carcinoma
rahat
et
al
ciitaindepend
mhc
class
express
could
upregul
histon
deacetylas
like
trichostatin
tsa
chou
et
al
gialitaki
et
al
ciita
refractori
ifn
induct
mani
tumor
colorect
gastric
carcinoma
cell
ciita
silenc
epigenet
mechan
result
lack
ifn
induc
mhc
class
ii
express
satoh
et
al
order
correl
ifn
unrespons
express
profil
isg
cdna
microarray
analys
employ
use
custom
microarray
consist
isg
holko
william
express
gene
associ
transcript
preced
express
gene
involv
signal
transduct
wherea
differ
induct
observ
howev
subtl
alter
express
profil
might
respons
insensit
cytokin
mainten
transcript
activ
follow
ifn
treatment
appear
enhanc
ifn
sensit
ifn
use
variou
clinic
set
sinc
potent
neg
regul
cell
growth
either
modul
cell
cycl
induc
proapoptot
gene
ifnha
extens
studi
treatment
variou
malign
last
two
decad
demonstr
improv
clinic
outcom
hematolog
malign
chronic
myeloid
leukemia
cutan
tcell
lymphoma
hairycel
leukemia
multipl
myeloma
solid
tumor
includ
malign
melanoma
renalcel
carcinoma
rcc
aidsrel
kaposi
sarcoma
viral
syndrom
hepat
c
hepat
b
sever
acut
respiratori
syndrom
ifnha
shown
posit
result
treatment
chronic
granulomat
diseas
multipl
sclerosi
sever
malign
osteopetrosi
parmar
platania
review
howev
resist
ifn
describ
limit
anticanc
activ
impair
express
ifnrespons
gene
might
import
implic
immunotherapi
also
transplant
pregnanc
develop
tumor
choriocarcinoma
despit
proven
clinic
efficaci
malign
viral
infect
multipl
sclerosi
substanti
number
patient
fail
develop
posit
clinic
respons
ifn
therapi
although
clinic
activ
therapeut
agent
malign
melanoma
rcc
patient
metastat
melanoma
respond
ifn
therapi
marincola
et
al
review
report
even
lower
respons
rate
treat
melanoma
patient
quesada
et
al
umeda
niijima
rcc
best
result
ifn
treatment
determin
respons
rate
durat
effect
obtain
patient
previou
nephrectomi
without
chemotherapi
good
function
state
preferenti
lung
metastasi
patient
surviv
rate
increas
week
upon
ifnadministr
logotheti
despit
posit
result
exist
mani
aspect
respons
factor
well
understood
actual
none
factor
prove
associ
unambigu
way
cytokin
respons
patient
surviv
key
aspect
may
right
select
patient
sinc
current
independ
previou
nephrectomi
presenc
metastasi
enrol
treatment
poor
clinic
outcom
unlik
type
ifn
ifnha
approv
cancer
treatment
fda
ifnproduc
numer
antitumor
effect
play
central
role
promot
natur
immun
respons
direct
develop
tumor
howev
practic
applic
immunotherapeut
protocol
limit
clinic
trial
improv
surviv
observ
patient
ovarian
cancer
stage
iciiic
treat
ifn
windbichl
et
al
ifn
intraves
administ
patient
transitionalcel
bladder
carcinoma
giannopoulo
et
al
ifn
use
isolatedlimb
perfus
individu
nonmelanoma
cancer
extrem
lienard
et
al
howev
effect
detect
upon
ifntreat
patient
metastat
rcc
gleav
et
al
advanc
colon
cancer
wiesenfeld
et
al
smallcel
lung
cancer
jett
et
al
limit
success
therapeut
use
ifnmight
reflect
inabl
target
ifn
right
place
effici
concentr
dunn
et
al
despit
proven
pivot
role
endogen
produc
antitumor
immun
ifnin
anim
model
limit
success
cytokin
cancer
immunotherapi
trial
human
might
explain
resist
tumor
cell
ifn
kaplan
et
al
rodriguez
et
al
wong
et
al
context
import
note
unlik
type
ifn
ifnha
direct
effect
tumor
cell
antitumor
immun
respons
support
relev
ifnin
cancer
immunoedit
process
dunn
et
al
target
immunolog
unrespons
repres
gene
encod
compon
mhc
apm
compon
constitu
ifnr
signal
pathway
context
two
recent
studi
laboratori
physiolog
relev
hla
class
surfac
express
tumor
reject
process
patient
receiv
differ
protocol
immunotherapi
assess
cabrera
et
al
carretero
et
al
submit
first
studi
signific
differ
immunotherapeut
respons
patient
exhibit
metastas
low
level
mhc
class
surfac
antigen
high
level
mhc
class
express
detect
second
trial
impact
cytokin
unrespons
demonstr
determin
hla
class
antigen
express
level
metastat
melanoma
lesion
cours
diseas
one
patient
undergo
autolog
vaccin
plu
bcg
mvax
bcg
trigger
induc
upregul
gene
associ
antigen
present
feinberg
et
al
saban
et
al
level
mhc
class
antigen
express
depend
ifn
respons
sinc
neither
progressor
metastas
increas
express
hla
class
antigen
vaccin
howev
signific
increas
hla
class
surfac
express
detect
regressor
metastas
therefor
hla
class
surfac
antigen
tumor
cell
significantli
contribut
therapeut
effect
bcg
connect
find
downregul
hla
class
surfac
antigen
cancer
cell
consid
signific
risk
factor
recurr
patient
intraves
bcg
immunotherapi
bladder
cancer
kitamura
et
al
base
result
better
understand
molecular
mechan
tumor
modul
cytokin
signal
may
essenti
develop
immunotherapeut
strategi
aim
enhanc
mhc
class
surfac
antigen
express
tumor
cell
balanc
stat
phosphoryl
versu
soc
express
might
crucial
activ
immunolog
respons
apm
mhc
class
transactiv
wang
et
al
instanc
effect
highdos
ifn
associ
immunolog
process
upregul
tpn
pathway
melanoma
cell
sensit
ifnbi
pretreat
cell
ifn
thu
biolog
respons
ifnmight
mediat
direct
effect
melanoma
cell
suggest
also
potenti
role
ifnin
treatment
diseas
carson
addit
recent
demonstr
ifntreat
patient
cutan
melanoma
significantli
modul
balanc
tumor
cell
host
lymphocyt
result
upregul
increas
immun
respons
wang
et
al
increas
knowledg
factor
respons
resist
ifn
might
lead
improv
use
cytokin
malign
diseas
applic
molecular
analysi
tumor
tissu
advanc
point
better
classif
scheme
prognost
variabl
use
lead
optim
specif
treatment
program
patient
select
identif
tumor
lesion
capac
upregul
mhc
gene
express
determin
abil
present
new
antigen
peptid
lymphocyt
favor
regress
primari
metastat
tumor
lesion
contrast
identif
tumor
mhc
irrevers
genet
lesion
maintain
unalt
mhc
express
therebi
expos
new
antigen
peptid
cell
subsequ
favor
tumor
andor
metastas
progress
propos
suppress
ifn
signal
tumor
contribut
toler
inhibit
express
gene
encod
subunit
hla
class
iii
antigen
andor
compon
mhc
class
iii
apm
could
detriment
success
antitumor
respons
